Prats Viñas J, Gallego Melcón S, Pérez Payarols J, Macía Martí J, Sánchez de Toledo J
An Esp Pediatr. 1987 Jan;26(1):15-21.
From january 1982 to january 1986 we treated 23 pediatric patients who had non Hodgkin's lymphoma, with a new therapeutic protocol. This protocol is based on the LSA2 L2, modified during the induction phase with high-dose methotrexate and increasing of intrathecal therapy. Nineteen patients (83%) were in stages III and IV and the 47.4% were in stage IV. The distribution according to histology was: 10 Burkitt's undifferentiated lymphomas; 2 non-Burkitt's undifferentiated lymphomas; 5 lymphoblastic lymphomas convoluted-cells; 5 lymphoblastic lymphoma non-convoluted cells and 1 indeterminate lymphoma. The follow-up oscillated between 6 months and 4 years. The total survival rate is 82.6% with a 100% survival in stages I, II and III and 63.5% in stage IV. The survival according histology is 91.7% for undifferentiated lymphomas and 70% for lymphoblastic lymphomas; the actuarial survival rates in the two groups at 30 months are 87% and 55% respectively (p greater than 0.10). We concluded that adding high-dose methotrexate to the LSA2 L2 protocol improve the survival rate in undifferentiated lymphomas and in a less extent in lymphoblastic lymphomas, without significant toxicity. This new protocol is mainly indicated in undifferentiated and indeterminate non-Hodgkin's lymphomas.
1982年1月至1986年1月，我们采用一种新的治疗方案治疗了23例患有非霍奇金淋巴瘤的儿科患者。该方案基于LSA2 L2，在诱导期用大剂量甲氨蝶呤和增加鞘内治疗进行了改良。19例患者（83%）处于III期和IV期，47.4%处于IV期。根据组织学分布为：10例伯基特未分化淋巴瘤；2例非伯基特未分化淋巴瘤；5例卷曲细胞淋巴母细胞淋巴瘤；5例非卷曲细胞淋巴母细胞淋巴瘤和1例未定型淋巴瘤。随访时间在6个月至4年之间。总生存率为82.6%，I期、II期和III期生存率为100%，IV期为63.5%。未分化淋巴瘤的组织学生存率为91.7%，淋巴母细胞淋巴瘤为70%；两组在30个月时的精算生存率分别为87%和55%（p大于0.10）。我们得出结论，在LSA2 L2方案中添加大剂量甲氨蝶呤可提高未分化淋巴瘤的生存率，对淋巴母细胞淋巴瘤的提高程度较小，且无明显毒性。这种新方案主要适用于未分化和未定型非霍奇金淋巴瘤。
